Percutaneous cholecystostomy: An update for the 2020s
Executive Summary
Percutaneous cholecystostomy (PC) serves as a critical, life-saving intervention for patients with acute cholecystitis who are deemed high-risk for standard surgical treatments. While laparoscopic cholecystectomy remains the gold standard, advanced age and significant comorbidities often make surgery prohibitive. PC offers a bridge to surgery or, in many cases, a definitive treatment for the disease.
Current data indicates that PC achieves a technical success rate of approximately 95% to 97.9%, with clinical success rates ranging between 60% and 90%. While 30-day mortality for these patients is high (8% to 36%) due to their underlying health status, mortality directly attributable to the procedure is exceptionally low, averaging only 0.35% to 0.36%. Given its effectiveness and minimal absolute contraindications, PC is an essential tool in managing gallbladder disease in the 2020s.
Clinical Indications and Patient Selection
The primary role of PC is the management of acute cholecystitis in patients where surgical intervention poses a significant risk to life.
Primary Indications
High Surgical Risk: Radiologically diagnosed acute cholecystitis in patients with temporary or permanent contraindications for surgery.
Biliary Drainage Failure: Inability to catheterize the intrahepatic biliary tract during attempted percutaneous biliary drainage.
Empiric Use: Cholecystostomy performed for fever of unknown origin.
Contraindications
Because PC is often performed in life-threatening scenarios where no other options exist, it has no absolute contraindications, with the possible exception of intestinal interposition blocking the access trajectory.
Relative Contraindications include:
Ascites along the access route.
Massive gallstones that prevent the locking of the catheter’s pigtail loop.
Coagulopathy or use of antiplatelets/anticoagulants (though studies show no significant difference in complication rates for these patients).
Pre-Procedural Evaluation and Risk Assessment
A detailed, rapid assessment is required to guide management and predict outcomes.
Severity Grading and Classification
Patients are graded using the Tokyo Guidelines 2018 (TG18) for acute cholecystitis. This grading determines the timing of drainage, surgical intervention, and antibiotic therapy. High-risk candidates are further identified using:
Charlson Comorbidity Index (CCI): Originally for long-term survival, it provides a simple indicator for patients with short life expectancy.
American Society of Anesthesiologists (ASA) scores.
Risk Factors to Monitor
Physicians must record primary and secondary factors including:
Cardiovascular, respiratory, renal, and hepatic dysfunction.
Duration of complaints (>72 hours).
Presence of a palpable tender mass or marked local inflammation.
Specific comorbidities such as diabetes mellitus, congestive heart failure, chronic obstructive pulmonary disease, and liver disease.
Procedural Methodology
Technical success depends on strict adherence to guidance methods and invasive techniques.
Guidance and Positioning
Method: Ultrasound (USG) guidance using a multiband convex array transducer is preferred. Fluoroscopy may be used as an adjunct.
Position: Left semi-lateral decubitus position on a flexed operating table is ideal to broaden intercostal distances.
Prophylaxis
Antibiotics: A second-generation cephalosporin (e.g., cefuroxime) is administered for Gram-negative coverage.
Disinfection: 7.5% povidone-iodine is used from the axillary line to the iliac crest.
Invasive Steps
Access: The transhepatic approach is preferred (traversing segment 5 or 6 of the liver). This approach secures the catheter through at least 10 mm of parenchyma, preventing leakage and ensuring tract maturation.
Aspiration: Approximately 10 ml of bile is aspirated immediately after needle entry for microbiological analysis and to prevent leakage during dilation.
The Seldinger Method: Single-step catheterization is avoided to protect the fragile gallbladder wall.
Dilation and Catheterization: The tract is dilated with 6 F and 8 F fascial dilators. An 8 F pigtail drainage catheter is then advanced over a super-stiff guide wire.
Fixation: The catheter is advanced to form a loop in the lumen and then sutured to the skin.
Follow-up and Success Metrics
Follow-up Schedule
3 Days: Clinical assessment of pain, fever, and laboratory markers (White Blood Cell count and C-reactive protein).
1 and 4 Weeks: USG to verify catheter position and mechanical efficacy.
6 Weeks: Removal under fluoroscopy after verifying cystic duct patency and tract maturity.
Success Rates
Technical Success: 95%–97.9% (threshold of 97.9% recommended by the Society of Interventional Radiology).
Clinical Success: 60%–90%. Resolution of pain and inflammatory markers is expected within 48–72 hours of catheter insertion.
Complications and Mortality
PC is considered a low-risk procedure with a complication rate between 0% and 9%.
Procedural Complications
Minor (Most Common): Catheter dislodgement (7%–7.6%), catheter blockage (7%–7.5%), and minor bile leakage (2.8%–3%).
Major: Sepsis (3.5%–5%), major hemorrhage (0.9%–1.4%), and bowel/pleural injury (0.35%–1.4%).
Mortality Analysis
PC as Bridge vs. Definitive Treatment
While traditionally seen as a "bridge to surgery," recent evidence suggests PC may be the final treatment for a significant portion of high-risk patients.
Bridge to Surgery: Temporizes patients until they are stable enough for laparoscopic or open cholecystectomy.
Definitive Treatment: Reported success rates for PC as a final treatment range from 43% to 94%. One study noted that 86% of patients required no further surgery following PC.
The low recurrence rate makes PC a viable definitive option for those who may never become suitable candidates for general anesthesia or invasive surgery.
